The new Hydrasolve liposuction device has recently been FDA-cleared for autologous fat transfer, a first-of-its-kind indication in the liposuction realm. The new clearance enables clinicians to harvest and re-inject fat from the initial HydraSolve liposuction procedure for rejuvenations or augmentation. Hydrasolve is a novel liposuction device based on the same patented Liquefaction Technology that was launched in 2003 by Alcon as the AquaLase Liquefaction Device, for precision cataract surgery. The device combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue by cell disaggregation, rather than emulsification and lysing of cell membranes. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required.